- Home
- DHT vs NEO Comparison
DHT vs NEO Comparison
Compare DHT & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHT | NEO |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.2B |
| IPO Year | 2005 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DHT | NEO |
|---|---|---|
| Price | $12.66 | $11.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $15.67 | $12.56 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 02-04-2026 | 10-28-2025 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | ★ 23.62 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | $538,571,000.00 | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.90 |
| Revenue Next Year | $41.15 | $9.88 |
| P/E Ratio | $10.21 | ★ N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $8.67 | $4.72 |
| 52 Week High | $13.85 | $19.12 |
Technical Indicators
Market Signals| Indicator | DHT | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 58.21 |
| Support Level | $12.40 | $11.46 |
| Resistance Level | $12.81 | $12.19 |
| Average True Range (ATR) | 0.25 | 0.37 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 30.29 | 45.01 |
Price Performance
Historical ComparisonAbout DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.